|
|
 Previous Article | Table of Contents | Next Article 
Follow-up observations on the effect of human leukocyte interferon in
non-Hodgkin's lymphoma
AC Louie, JG Gallagher, K Sikora, R Levy, SA Rosenberg and TC Merigan
Follow-up data for 11 patients with non-Hodgkin's lymphoma treated with
partially purified human leukocyte interferon is presented. The interferon
preparation used was 0.1% pure and treatment consisted of 5 x 10(6) U given
intramuscularly twice daily for 60 injections. One complete, three partial,
and three minimal responses were observed in five of seven evaluable
patients with nodular non-Hodgkin's lymphoma. Duration of response appears
to be from 6 to 12 mo. One patient achieved a second partial response on
retreatment with interferon in spite of having received chemotherapy in the
interval between interferon treatments. No responses were seen in three
patients with rapidly progressive diffuse histiocytic lymphoma.
Dose-limiting toxicity is leukopenia, which necessitated modification or
cessation of treatment in three patients. Nonhematologic toxicities
consisted of fever, malaise, arthralgia, and loss of appetite. In
conclusion, interferon has activity against non-Hodgkin's lymphoma, and
prior treatment with chemotherapy does not preclude a response to
interferon.
Volume 58,
Issue 4,
pp. 712-718,
10/01/1981
Copyright © 1981 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A.Z.S. Rohatiner, W.M. Gregory, B. Peterson, E. Borden, P. Solal-Celigny, A. Hagenbeek, R.I. Fisher, M. Unterhalt, R. Arranz, T. Chisesi, et al.
Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma
J. Clin. Oncol.,
April 1, 2005;
23(10):
2215 - 2223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Foon, K. R. Rai, and R. P. Gale
Chronic Lymphocytic Leukemia: New Insights into Biology and Therapy
Ann Intern Med,
October 1, 1990;
113(7):
525 - 539.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. D. CHESON and A. MARTIN
Clinical Trials in Hairy Cell Leukemia: Current Status and Future Directions
Ann Intern Med,
June 1, 1987;
106(6):
871 - 878.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. L. FAHEY, G. SARNA, R. P. GALE, and R. SEEGER
Immune Interventions in Disease
Ann Intern Med,
February 1, 1987;
106(2):
257 - 274.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. CHAMPLIN, R. P. GALE, K. A. FOON, and D. W. GOLDE
Chronic Leukemias: Oncogenes, Chromosomes, and Advances in Therapy
Ann Intern Med,
May 1, 1986;
104(5):
671 - 688.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. P. GALE and K. A. FOON
Chronic Lymphocytic Leukemia: Recent Advances in Biology and Treatment
Ann Intern Med,
July 1, 1985;
103(1):
101 - 120.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. A. BUNN Jr., K. A. FOON, D. C. IHDE, D. L. LONGO, J. EDDY, C. F. WINKLER, S. R. VEACH, J. ZEFFREN, S. SHERWIN, and R. OLDHAM
Recombinant Leukocyte A Interferon: An Active Agent in Advanced Cutaneous T-Cell Lymphomas
Ann Intern Med,
October 1, 1984;
101(4):
484 - 487.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. A. SHERWIN, D. MAYER, J. J. OCHS, P. G. ABRAMS, J. A. KNOST, K. A. FOON, S. FEIN, and R. K. OLDHAM
Recombinant Leukocyte A Interferon in Advanced Breast Cancer: Results of a Phase II Efficacy Trial
Ann Intern Med,
May 1, 1983;
98(5_Part_1):
598 - 602.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. A. Sherwin, J. A. Knost, S. Fein, P. G. Abrams, K. A. Foon, J. J. Ochs, C. Schoenberger, A. E. Maluish, and R. K. Oldham
A Multiple-Dose Phase I Trial of Recombinant Leukocyte A Interferon in Cancer Patients
JAMA,
November 19, 1982;
248(19):
2461 - 2466.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. J. Horning, J. F. Levine, R. A. Miller, S. A. Rosenberg, and T. C. Merigan
Clinical and Immunologic Effects of Recombinant Leukocyte A Interferon in Eight Patients With Advanced Cancer
JAMA,
March 26, 1982;
247(12):
1718 - 1722.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. R. STIEHM, L. H. KRONENBERG, H. M. ROSENBLATT, Y. BRYSON, and T. C. MERIGAN
Interferon: Immunobiology and Clinical Significance
Ann Intern Med,
January 1, 1982;
96(1):
80 - 93.
[Abstract]
[PDF]
|
|
|
|
|
